Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oral human gammaglobulin

Drug Profile

Oral human gammaglobulin

Alternative Names: IgPO; Oralgam

Latest Information Update: 09 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sepulveda Ambulatory Care Center; University of California at Los Angeles
  • Developer Protein Therapeutics; Research Corporation Technologies; University of California at Los Angeles
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis; Enterocolitis; Juvenile rheumatoid arthritis
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Crohn's disease; Enterocolitis; Juvenile rheumatoid arthritis; Rheumatoid arthritis

Most Recent Events

  • 29 Apr 2008 Oral gammaglobulin (Oralgam™) licensed to Latona Life Sciences worldwide for the treatment of Juvenile and adult rheumatoid arthritis and auto-immune induced hearing loss
  • 24 Feb 2006 Phase-II clinical trials in Enterocolitis in USA (PO)
  • 24 Feb 2006 PediaMed has completed enrolment in a phase II trial for Autistic enterocolitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top